<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00474435</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF 04.03</org_study_id>
    <nct_id>NCT00474435</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Tuberculosis</brief_title>
  <acronym>PETE</acronym>
  <official_title>The Pharmacokinetics of Co-formulated Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Smear-positive Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>African Poverty Related Infection Oriented Research Initiative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kilimanjaro Christian Medical Centre, Tanzania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>African Poverty Related Infection Oriented Research Initiative</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this pilot study the pharmacokinetics and safety of the antiretroviral combination of
      co-formulated emtricitabine/tenofovir/efavirenz will be studied in HIV-positive patients with
      pulmonary tuberculosis (TB) who are concomitantly treated with a standard rifampin-containing
      tuberculostatic regimen. It is expected that this antiretroviral combination causes minimal
      drug interactions with the rifampin-containing anti-tuberculosis medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives of this pilot study in 30 patients are:

        1. To determine the effect of rifampin-containing tuberculostatic treatment on the
           pharmacokinetic profile of emtricitabine+tenofovir+efavirenz, when co-formulated in one
           tablet, in HIV-infected patients with smear-positive pulmonary tuberculosis in Tanzania.

        2. To determine the effect of the emtricitabine+tenofovir+efavirenz regimen on the
           pharmacokinetics of tuberculostatics in the same population.

      The secondary objectives are:

        1. To determine the safety of co-administration of emtricitabine+tenofovir+efavirenz with
           treatment for smear-positive pulmonary tuberculosis.

        2. To determine the short-term (24 weeks) virological efficacy on HIV of an
           emtricitabine+tenofovir+efavirenz regimen in patients with smear-positive pulmonary
           tuberculosis.

        3. To determine the short-term bacteriological efficacy on smear-positive tuberculosis of
           the co-administration of a standard regimen for tuberculosis and an
           emtricitabine+tenofovir+efavirenz regimen.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of emtricitabine, tenofovir and efavirenz</measure>
    <time_frame>Two 24 hour pharmacokinetic (PK) curves (week 8 and 28)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of the tuberculostatic agents</measure>
    <time_frame>Pharmacokinetic (PK) samples at 2 hours and 6 hours postdose (week 2 and 8)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemistry and haematology samples for safety</measure>
    <time_frame>Samples at screening, baseline, week 2, 4, 6, 8, 12, 16, 24, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questioning about occurrence of adverse events</measure>
    <time_frame>At baseline, week 2, 4, 6, 8, 12, 16, 24, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 count and HIV-1 RNA</measure>
    <time_frame>At screening, week 4, week 16 and week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum staining and culture</measure>
    <time_frame>At screening, week 4, 8, and 28</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Tuberculosis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine/tenofovir/efavirenz</intervention_name>
    <description>Co-formulated in one tablet (taken once daily by oral administration):
emtricitabine 200 mg
tenofovir DF 300 mg
efavirenz 600 mg</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A smear-positive pulmonary tuberculosis, based on positive smear of at least two
             sputum samples with Ziehl-Neelsen (ZN) staining.

          -  HIV-infected as documented by positive HIV antibody test.

          -  Subject is at least 18 years of age at the day of the first dosing of study
             medication.

          -  Subject is able and willing to sign the Informed Consent Form prior to screening
             evaluations.

          -  CD4 cell count &gt; 50 copies/mm3.

          -  Karnofsky score &gt; 40.

          -  Willing and able to regularly attend the Kibung'oto National Tuberculosis Hospital
             (KNTH) clinic.

        Exclusion Criteria:

          -  History of sensitivity/idiosyncrasy to the drug or chemically related compounds or
             excipients, which may be employed in the trial.

          -  Previously treated for HIV infection with antiretroviral agents.

          -  Pregnant or breastfeeding.

          -  Relevant history or current condition that might interfere with drug absorption,
             distribution, metabolism or excretion.

          -  A history of severe psychiatric disease such as psychosis, schizophrenia, etc.

          -  Inability to understand the nature and extent of the trial and the procedures
             required.

          -  Abnormal serum transaminases or creatinine, determined as levels being &gt; 5 times upper
             limit of normal.

          -  Active hepatobiliary or hepatic disease (Non B Chronic Hepatitis B/C co-infection is
             allowed).

          -  CD4 cell count &gt; 350 cells/mm3.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Boeree, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Lungcentre Dekkerswald, Groesbeek / University Medical Centre Nijmegen, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Burger, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Nijmegen, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gibson Kibiki, MMed, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kilimanjaro Christian Medical Centre,Moshi,Tanzania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gibson Kibiki, MMed, PhD</last_name>
    <phone>+255 754 572767</phone>
    <email>gkibiki@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jossy van den Boogaard, MD</last_name>
    <phone>+255 787 148431</phone>
    <email>jossyvandenboogaard@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kibong'oto National Tuberculosis Hospital</name>
      <address>
        <city>Moshi</city>
        <state>Kilimanjaro Region</state>
        <zip>P.O. Box 12</zip>
        <country>Tanzania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liberate Mleoh, MD</last_name>
      <phone>027 2756194</phone>
      <email>lmleoh@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Gibson Kibiki, MMed, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elton Kisanga, B-Pharm, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liberate Mleoh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jossy van den Boogaard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hadija Semvua, B-Pharm, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Mtabho, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <reference>
    <citation>Bowen EF, Rice PS, Cooke NT, Whitfield RJ, Rayner CF. HIV seroprevalence by anonymous testing in patients with Mycobacterium tuberculosis and in tuberculosis contacts. Lancet. 2000 Oct 28;356(9240):1488-9.</citation>
    <PMID>11081535</PMID>
  </reference>
  <reference>
    <citation>Msamanga GI, Fawzi WW. The double burden of HIV infection and tuberculosis in sub-Saharan Africa. N Engl J Med. 1997 Sep 18;337(12):849-51.</citation>
    <PMID>9295244</PMID>
  </reference>
  <reference>
    <citation>Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, Fisher M, Taylor GP, Miller R, Taylor CB, de Ruiter A, Pozniak AL. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS. 2002 Jan 4;16(1):75-83.</citation>
    <PMID>11741165</PMID>
  </reference>
  <reference>
    <citation>Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet. 2001;40(5):327-41. Review.</citation>
    <PMID>11432536</PMID>
  </reference>
  <reference>
    <citation>Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. Arch Intern Med. 2002 May 13;162(9):985-92. Review.</citation>
    <PMID>11996607</PMID>
  </reference>
  <reference>
    <citation>López-Cortés LF, Ruiz-Valderas R, Viciana P, Alarcón-González A, Gómez-Mateos J, León-Jimenez E, Sarasanacenta M, López-Pua Y, Pachón J. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002;41(9):681-90.</citation>
    <PMID>12126459</PMID>
  </reference>
  <reference>
    <citation>Burger DM, Meenhorst PL, Koks CH, Beijnen JH. Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob Agents Chemother. 1993 Jul;37(7):1426-31.</citation>
    <PMID>8363370</PMID>
  </reference>
  <reference>
    <citation>Gallicano KD, Sahai J, Shukla VK, Seguin I, Pakuts A, Kwok D, Foster BC, Cameron DW. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br J Clin Pharmacol. 1999 Aug;48(2):168-79.</citation>
    <PMID>10417493</PMID>
  </reference>
  <reference>
    <citation>Friedland G, Abdool Karim S, Abdool Karim Q, Lalloo U, Jack C, Gandhi N, El Sadr W. Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries. Clin Infect Dis. 2004 Jun 1;38 Suppl 5:S421-8.</citation>
    <PMID>15156433</PMID>
  </reference>
  <reference>
    <citation>Droste JA, Aarnoutse RE, Koopmans PP, Hekster YA, Burger DM. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):287-91.</citation>
    <PMID>12626888</PMID>
  </reference>
  <reference>
    <citation>Holland DT, DiFrancesco R, Stone J, Hamzeh F, Connor JD, Morse GD; Adult and Pediatric AIDS Clinical Trials Group Pharmacology Laboratory Committees, Pediatric AIDS Clinical Trials Group. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother. 2004 Mar;48(3):824-31.</citation>
    <PMID>14982771</PMID>
  </reference>
  <reference>
    <citation>Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001 Jan 5;15(1):71-5.</citation>
    <PMID>11192870</PMID>
  </reference>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2007</study_first_submitted>
  <study_first_submitted_qc>May 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2007</study_first_posted>
  <last_update_submitted>December 16, 2010</last_update_submitted>
  <last_update_submitted_qc>December 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Martin Boeree</name_title>
    <organization>University Lungcentre Dekkerswald, Groesbeek, the Netherlands</organization>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>HIV</keyword>
  <keyword>Coinfection</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Emtricitabine</keyword>
  <keyword>Tenofovir</keyword>
  <keyword>Rifampin</keyword>
  <keyword>Efavirenz</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

